Shared on 10 Dec 25

Fair value Increased 0.39%

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.

Shared on 26 Nov 25

Fair value Increased 0.76%

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.

Shared on 12 Nov 25

Fair value Increased 2.42%

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.

Shared on 29 Oct 25

Fair value Increased 0.12%

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.

Shared on 15 Oct 25

Fair value Increased 1.36%

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.

Shared on 20 Sep 25

Fair value Decreased 1.12%

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.

Shared on 05 Sep 25

Fair value Increased 1.49%

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.

Shared on 07 May 25

Fair value Decreased 7.67%

Shared on 30 Apr 25

Fair value Decreased 4.99%

AnalystConsensusTarget has increased revenue growth from -1.4% to -1.7%.

Shared on 23 Apr 25

Fair value Decreased 0.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 3.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 14%

Shared on 10 Mar 25

Fair value Decreased 9.33%

AnalystConsensusTarget has decreased revenue growth from 0.7% to -1.5% and decreased profit margin from 25.7% to 22.9%.

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Shared on 29 Oct 25

Shared on 15 Oct 25

Shared on 20 Sep 25

Shared on 05 Sep 25

Shared on 07 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 16 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 10 Mar 25